Abstract
Rho GTPases play a key role in the regulation of multiple essential cellular processes, including actin dynamics, gene transcription and cell cycle progression. Aberrant activation of Rac1, a member of Rho family of small GTPases, is associated with tumorigenesis, cancer progression, invasion and metastasis. Particularly, Rac1 is overexpressed and hyperactivated in highly aggressive breast cancer. Thus, Rac1 appears to be a promising and relevant target for the development of novel anticancer drugs. We identified the novel Rac1 inhibitor ZINC69391 through a docking-based virtual library screening targeting Rac1 activation by GEFs. This compound was able to block Rac1 interaction with its GEF Tiam1, prevented EGF-induced Rac1 activation and inhibited cell proliferation, cell migration and cell cycle progression in highly aggressive breast cancer cell lines. Moreover, ZINC69391 showed an in vivo antimetastatic effect in a syngeneic animal model. We further developed the novel analog 1A-116 by rational design and showed to be specific and more potent than the parental compound in vitro and interfered Rac1-P-Rex1 interaction. We also showed an enhanced in vivo potency of 1A-116 analog. These results show that we have developed novel Rac1 inhibitors that may be used as a novel anticancer therapy.
Keywords: Breast cancer, docking, Rac1 inhibitor, rational design, virtual screening.
Anti-Cancer Agents in Medicinal Chemistry
Title:Preclinical Development of Novel Rac1-GEF Signaling Inhibitors using a Rational Design Approach in Highly Aggressive Breast Cancer Cell Lines
Volume: 14 Issue: 6
Author(s): Georgina A. Cardama, Maria J. Comin, Leandro Hornos, Nazareno Gonzalez, Lucas Defelipe, Adrian G. Turjanski, Daniel F. Alonso, Daniel E. Gomez and Pablo Lorenzano Menna
Affiliation:
Keywords: Breast cancer, docking, Rac1 inhibitor, rational design, virtual screening.
Abstract: Rho GTPases play a key role in the regulation of multiple essential cellular processes, including actin dynamics, gene transcription and cell cycle progression. Aberrant activation of Rac1, a member of Rho family of small GTPases, is associated with tumorigenesis, cancer progression, invasion and metastasis. Particularly, Rac1 is overexpressed and hyperactivated in highly aggressive breast cancer. Thus, Rac1 appears to be a promising and relevant target for the development of novel anticancer drugs. We identified the novel Rac1 inhibitor ZINC69391 through a docking-based virtual library screening targeting Rac1 activation by GEFs. This compound was able to block Rac1 interaction with its GEF Tiam1, prevented EGF-induced Rac1 activation and inhibited cell proliferation, cell migration and cell cycle progression in highly aggressive breast cancer cell lines. Moreover, ZINC69391 showed an in vivo antimetastatic effect in a syngeneic animal model. We further developed the novel analog 1A-116 by rational design and showed to be specific and more potent than the parental compound in vitro and interfered Rac1-P-Rex1 interaction. We also showed an enhanced in vivo potency of 1A-116 analog. These results show that we have developed novel Rac1 inhibitors that may be used as a novel anticancer therapy.
Export Options
About this article
Cite this article as:
Cardama A. Georgina, Comin J. Maria, Hornos Leandro, Gonzalez Nazareno, Defelipe Lucas, Turjanski G. Adrian, Alonso F. Daniel, Gomez E. Daniel and Menna Lorenzano Pablo, Preclinical Development of Novel Rac1-GEF Signaling Inhibitors using a Rational Design Approach in Highly Aggressive Breast Cancer Cell Lines, Anti-Cancer Agents in Medicinal Chemistry 2014; 14 (6) . https://dx.doi.org/10.2174/18715206113136660334
DOI https://dx.doi.org/10.2174/18715206113136660334 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Promising Anticancer Drug Candidates Based on the 7-methoxychromone Scaffold: Synthesis and Evaluation of Antiproliferative Activity
Letters in Drug Design & Discovery The Need for Diagnostic Criteria in Systemic Vasculitis
Current Immunology Reviews (Discontinued) Iron Oxide Nanoparticles: An Insight into their Biomedical Applications
Current Medicinal Chemistry Solid Lipid Nanoparticles: A Promising Nanomaterial in Drug Delivery
Current Pharmaceutical Design Drug Targets from Genetics: Alpha-Synuclein
CNS & Neurological Disorders - Drug Targets The Molecular Basis of Herpesviruses as Oncolytic Agents
Current Pharmaceutical Biotechnology Thiomers, Mucoadhesion and Oral Delivery of Biomacromolecules
Current Drug Therapy Crosstalk between Gut Microbiota and Central Nervous System: A Focus on Alzheimer's Disease
Current Alzheimer Research Utilization of Lipid-based Nanoparticles to Improve the Therapeutic Benefits of Bortezomib
Anti-Cancer Agents in Medicinal Chemistry Meet Our Editorial Board Member
Current Cancer Drug Targets Immunomodulation in Polytrauma and Polymicrobial Sepsis - Where Do We Stand?
Recent Patents on Inflammation & Allergy Drug Discovery Importance of Pharmacology Knowledge by Dieticians
Current Nutrition & Food Science Zn(L-proline)2: An Efficient and Recyclable Catalytic System for the Asymmetric Multicomponent Synthesis of 2-amino-4H-chromenes in Water Under Controlled Microwave Heating
Current Microwave Chemistry Understanding Membrane Protein Drug Targets in Computational Perspective
Current Drug Targets Editorial (Moving Beyond Our Mutual Ignorance. Or, How would Engaging the Public Benefit the Personalized Medicine Community?)
Current Pharmacogenomics and Personalized Medicine Targeting JAK3 Tyrosine Kinase-Linked Signal Transduction Pathways with Rationally-Designed Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Establishment of Novel Cells Stably Secreting Various Human IL-18 Recombinant Proteins
Current Pharmaceutical Biotechnology Targeted Cancer Therapy: The Next Generation of Cancer Treatment
Current Drug Discovery Technologies Signal Transduction by the Cytoplasmic Domain of NEUREGULIN-1 and its Roles During Neuronal Aging
Current Signal Transduction Therapy Clinico-Pathologic Function of Cerebral ABC Transporters – Implications for the Pathogenesis of Alzheimers Disease
Current Alzheimer Research